Therapeutic Area Market Research Reports & Industry Analysis
Therapeutic areas include Cardiology/Vascular Diseases, Dental and Oral Health, Dermatology, Devices, Endocrinology, Family Medicine, Gastroenterology, Genetic Disease, Healthy Volunteers, Hematology, Hepatology, Immunology, Infections and Infectious Diseases, Internal Medicine, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics/Gynecology, Oncology, Ophthalmology, Orthopedics/Orthopedic Surgery, Otolaryngology, Pediatrics/Neonatology, Pharmacology/Toxicology, Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Sleep, Trauma, Urology, and Vaccines.
Reports in these categories will contain statistics of prevalence and growth concerning therapeutic area diseases for which there are product reviews, market size, and share for products that are used in pharmaceutical treatment or equipment that used in surgical treatment of the therapeutic area.
Therapeutic Area Industry Research & Market Reports
-
Intravaginal Insemination
... CAGR of 7.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$130.1 Million While China is Forecast to Grow at 10.8% CAGR The Intravaginal Insemination market in the U.S. is estimated at ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Cancer Registry Software
... at a CAGR of 9.6% over the analysis period 2024-2030. Standalone, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$116.6 Million by the end of the ... Read More
-
Breakthrough Therapy (BT) Designation
... 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$138.3 Billion by the end ... Read More
-
Acute Repetitive Seizures
... at a CAGR of 45.4% over the analysis period 2024-2030. Diastat Rectal Gel, one of the segments analyzed in the report, is expected to record a 46.9% CAGR and reach US$8.4 Billion by the end ... Read More
-
Behavioral Rehabilitation
... CAGR of 6.0% over the analysis period 2024-2030. Outpatient, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$207.4 Billion by the end of the analysis period. ... Read More
-
Bioprosthetics
... 9.7% over the analysis period 2024-2030. Xenograft, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$8.3 Billion by the end of the analysis period. Growth in ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million by the ... Read More
-
Canine Atopic Dermatitis
... at a CAGR of 8.2% over the analysis period 2024-2030. Glucocorticoids, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.0 Billion by the end of the ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC), one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by the ... Read More
-
Disruptive Behavior Disorder (DBD) Treatment
... Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Oppositional Defiant Disorder, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$19.2 ... Read More
-
Doxorubicin
... 5.8% over the analysis period 2024-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth ... Read More
-
End-Stage Renal Disease
... at a CAGR of 11.7% over the analysis period 2024-2030. Hemodialysis, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$209.9 Billion by the end of the ... Read More
-
Glaucoma Surgery Devices
... at a CAGR of 21.0% over the analysis period 2024-2030. Traditional, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$3.1 Billion by the end of the ... Read More
-
Hemato Oncology Testing
... at a CAGR of 16.5% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$8.6 Billion by the end of the ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Radiodermatitis
... 4.2% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$412.0 Million by the end of the analysis period. Growth in ... Read More
-
Women's Health Therapeutics
... at a CAGR of 12.9% over the analysis period 2024-2030. Postmenopausal Osteoporosis, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$18.1 Billion by the end of ... Read More
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Soft Tissue Repair
... at a CAGR of 6.0% over the analysis period 2024-2030. Fixation Products, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$19.6 Billion by the end of ... Read More
-
Embolotherapy
... 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth ... Read More
-
Gastroesophageal Reflux Disease (GERD) Therapeutics
... Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.6 Billion by ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Intracranial Aneurysm
... CAGR of 8.7% over the analysis period 2024-2030. Endovascular Coiling, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
Research Assistance
